ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 2, Pages 346
Publisher
MDPI AG
Online
2021-01-19
DOI
10.3390/cancers13020346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2. Study protocol
- (2020) Jesper Nors et al. ACTA ONCOLOGICA
- Circulating tumor DNA-based decision for adjuvant treatment in colon cancer stage II evaluation: (CIRCULATE-trial) AIO-KRK-0217.
- (2020) Gunnar Folprecht et al. JOURNAL OF CLINICAL ONCOLOGY
- “Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial”
- (2020) Julien Taïeb et al. DIGESTIVE AND LIVER DISEASE
- Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia).
- (2020) Pashtoon Murtaza Kasi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
- (2020) Van K. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).
- (2020) Gayathri Anandappa et al. JOURNAL OF CLINICAL ONCOLOGY
- The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.
- (2020) Sara Lonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
- (2020) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.
- (2020) Jerome Galon et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of surgical trauma on circulating free DNA levels in cancer patients – implications for studies of circulating tumor DNA
- (2020) Tenna V. Henriksen et al. Molecular Oncology
- P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress)
- (2020) H. Yukami et al. ANNALS OF ONCOLOGY
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- (2020) Arvind Dasari et al. Nature Reviews Clinical Oncology
- 398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial
- (2020) C. Lepage et al. ANNALS OF ONCOLOGY
- Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study
- (2020) S. J. Schraa et al. BMC CANCER
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
- (2020) Jeanne Tie et al. INTERNATIONAL JOURNAL OF CANCER
- Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
- (2020) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy
- (2019) Wanxia Gai et al. Genes
- A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
- (2019) Aparna Raj Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline Summary
- (2019) Ainhoa Costas-Chavarri et al. Journal of Oncology Practice
- Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
- (2019) Isaac Garcia-Murillas et al. JAMA Oncology
- Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
- (2019) Bradon R. McDonald et al. Science Translational Medicine
- LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
- (2019) N Tarazona et al. ANNALS OF ONCOLOGY
- Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
- (2019) Hiroki Osumi et al. Scientific Reports
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
- (2019) Shelize Khakoo et al. CLINICAL CANCER RESEARCH
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
- (2018) J B Bachet et al. ANNALS OF ONCOLOGY
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
- (2018) Jeanne Tie et al. GUT
- Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies
- (2018) Lena Gorgannezhad et al. LAB ON A CHIP
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
- (2018) Ola Landgren et al. SEMINARS IN HEMATOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective
- (2017) Mathilde Postel et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
- (2017) Alan P. Venook et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Colorectal cancer-global burden, trends, and geographical variations
- (2017) Jeffrey Douaiher et al. JOURNAL OF SURGICAL ONCOLOGY
- False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer
- (2017) Anya Litvak et al. Journal of the National Comprehensive Cancer Network
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2016) D. Hoelzer et al. ANNALS OF ONCOLOGY
- Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
- (2016) J. Taieb et al. ANNALS OF ONCOLOGY
- Minimal residual disease is an independent predictor for 10-year survival in CLL
- (2016) M. Kwok et al. BLOOD
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)
- (2016) Donna Niedzwiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
- (2016) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
- (2016) Rachel S Kerr et al. LANCET ONCOLOGY
- Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies
- (2016) S. Volik et al. MOLECULAR CANCER RESEARCH
- Integrated digital error suppression for improved detection of circulating tumor DNA
- (2016) Aaron M Newman et al. NATURE BIOTECHNOLOGY
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- (2016) Jeanne Tie et al. Science Translational Medicine
- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
- (2015) J. Tie et al. ANNALS OF ONCOLOGY
- A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
- (2015) G. Rosati et al. ANNALS OF ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
- (2015) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)
- (2015) Deirdre R. Pachman et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer
- (2014) John N. Primrose et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Clinical relevance of circulating cell-free microRNAs in cancer
- (2014) Heidi Schwarzenbach et al. Nature Reviews Clinical Oncology
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) R. Labianca et al. ANNALS OF ONCOLOGY
- Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement
- (2013) Jeffrey A. Meyerhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry
- (2013) Floortje Mols et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01
- (2012) Kelley M. Kidwell et al. CANCER
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
- (2011) Benjamin J. Hindson et al. ANALYTICAL CHEMISTRY
- Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
- (2011) F. Buccisano et al. BLOOD
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- (2011) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
- (2011) Erin S. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection and quantification of rare mutations with massively parallel sequencing
- (2011) I. Kinde et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Review of biomarkers in colorectal cancer
- (2010) K. F. Newton et al. Colorectal Disease
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
- (2009) Daniel Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
- (2008) M. J. Borowitz et al. BLOOD
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started